arrow
J

James D. Phelan

national institutes of health
H指数:29
被引数:6,059

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Axes of biological variation in diffuse large B cell lymphoma

弥漫大B细胞淋巴瘤的生物变异轴

2026-01-150
PRE
An Assessment of Kinase Selectivity; Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors

对激酶选择性的评估;几种布鲁顿酪氨酸激酶(BTK)抑制剂的酶抑制动力学及体外活性

2025-11-180
OAAI
BLIMP1 negatively regulates IL-2 signaling in T cells

BLIMP1负向调控T细胞中的IL-2信号通路。

2025-07-180
OA
Phase lb/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naive Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease

维奈克拉、依鲁替尼、泼尼松、奥滨尤妥珠单抗和来那度胺(ViPOR)在复发/难治性及初治套细胞淋巴瘤中的lb/2期研究:安全性、有效性和微小残留病初步分析

BLOOD
IF23.1
2024-11-050
PRE
Gα13 restricts nutrient driven proliferation in mucosal germinal centers
2024-07-180
OAAI
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
2024-06-205
OAAI
Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
2024-04-251
OA
Molecular mechanism of action and targets of glucocorticoids in lymphoma therapy
2024-03-220
PRE
Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
2023-05-0412
OA
Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma (vol 13, 5469, 2022)
2022-10-030
OAAI
Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma
2022-09-1710
OAAI
A CRISPR screen targeting PI3K effectors identifies RASA3 as a negative regulator of LFA-1-mediated adhesion in T cells

靶向PI3K效应物的CRISPR筛选将RASA3鉴定为T细胞中LFA-1-mediated粘附的负调节因子

2022-07-1916
OA
Overcoming Acquired Epigenetic Resistance to BTK Inhibitors
2021-09-1437
OA
Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas
IMMUNITY
IF26.3
2021-01-0192
OAAI